-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CD38 inhibitor Sarclisa French pharmaceutical company Sanofi (Sanofi) a combination of carfilzomib and dexamethasone (Kd) and the treatment of advanced multiple myeloma has received US Food and Drug Administration Administration ( the FDA approved) of.
Manage FDA
Sarclisa (isatuximab) combined with Kd therapy is currently used in the United States to treat adult patients with relapsed or refractory multiple myeloma (RR MM), these patients have received one to three previous treatment options.
In the IKEMA Phase III study, Sarclisa combined with Kd reduced the risk of disease progression compared with standard care Kd using only RRMM.
There was no statistically significant difference in the overall response rate (ORR).
However, the complete response rate (CR) of the Sarclisa combination treatment group was 39.
Sarclisa has also been approved in the United States for use in combination with pomalidomide and dexamethasone (pom-dex) to treat adult patients with RRMM who have received at least two previous therapies.
Original source:
Original source:href="" target="_blank" rel="noopener">